EP2475636A1 - Procédé pour préparer des cristaux de forme a et forme b de dexkétoprofène trométamol - Google Patents
Procédé pour préparer des cristaux de forme a et forme b de dexkétoprofène trométamolInfo
- Publication number
- EP2475636A1 EP2475636A1 EP09786483A EP09786483A EP2475636A1 EP 2475636 A1 EP2475636 A1 EP 2475636A1 EP 09786483 A EP09786483 A EP 09786483A EP 09786483 A EP09786483 A EP 09786483A EP 2475636 A1 EP2475636 A1 EP 2475636A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dexketoprofen
- trometamol
- appropriate solvent
- crystallization
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- QUZMDHVOUNDEKW-MERQFXBCSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;(2s)-2-(3-benzoylphenyl)propanoic acid Chemical group OCC(N)(CO)CO.OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 QUZMDHVOUNDEKW-MERQFXBCSA-N 0.000 title claims abstract description 43
- 239000013078 crystal Substances 0.000 title claims description 19
- 238000004519 manufacturing process Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 52
- 229960005448 dexketoprofen trometamol Drugs 0.000 claims abstract description 33
- 239000002904 solvent Substances 0.000 claims description 62
- 229960000281 trometamol Drugs 0.000 claims description 31
- 238000002425 crystallisation Methods 0.000 claims description 29
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 29
- 229960002783 dexketoprofen Drugs 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 26
- DKYWVDODHFEZIM-NSHDSACASA-N dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 claims description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 230000008025 crystallization Effects 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 18
- 238000001816 cooling Methods 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 9
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 9
- 239000008096 xylene Substances 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 8
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 4
- 229940011051 isopropyl acetate Drugs 0.000 claims description 4
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 3
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 claims description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 2
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 2
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims 3
- 238000002441 X-ray diffraction Methods 0.000 claims 2
- WCSHSCIJJPTYAX-UHFFFAOYSA-N dichloromethane propyl acetate Chemical compound C(C)(=O)OCCC.C(Cl)Cl WCSHSCIJJPTYAX-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000011521 glass Substances 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000011877 solvent mixture Substances 0.000 description 12
- 238000001556 precipitation Methods 0.000 description 11
- 239000004809 Teflon Substances 0.000 description 6
- 229920006362 Teflon® Polymers 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 229940093499 ethyl acetate Drugs 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 5
- 238000000634 powder X-ray diffraction Methods 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 4
- 229960000991 ketoprofen Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- KGSSUTVUTPLSQW-UHFFFAOYSA-N Robustone Chemical compound C1=C2OCOC2=CC(C2=COC=3C=C4OC(C=CC4=C(O)C=3C2=O)(C)C)=C1 KGSSUTVUTPLSQW-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012296 anti-solvent Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- -1 alkyl hydrocarbons Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
Definitions
- This invention relates to simple, economic and reliable methods to prepare Dexke- toprofen Trometamol polymorphs of Form A and Form B.
- Ketoprofen is a well known member of non-steroidal anti-inflammatory drugs
- Ketoprofen has an asymetric carbon in its chemical structure and it is commercially available as a racemic mixture in the drug market.
- DKT Dexketoprofen trometamol
- trometamol salt of S (+) enantiomer of Ketoprofen which has superior properties compared to ketoprofen in point of view of solubility and efficacy. It is used mainly as analgesic and marketed by Menarini under the Keral ® trademark as tablet and other dosage forms.
- Polymorphism is a well known phenomen among pharmaceutical active compounds influencing properties such as solubility, stability, melting point among others and thus important .
- EP1739072 discloses that dexketoprofen trometamol also shows polymorphism.
- EP668851 patent points out a way of crystallization of dexketoprofen trometamol.
- the reaction is carried out in a single solvent containing dexketoprofen and trometamol.
- the reactants don't need to be completely soluble in the solvent .
- DKT is insoluble in these solvent systems and dexketoprofen and /or trometamol are less soluble in these solvents. This type of reaction leads to less degradation since DKT is insoluble in the solvent system thus less prone to
- Dexketoprofen and trometamol are dissolved in Ethanol / Ethylmethylketon mixture , Xylene is added onto it at elevated temperature to obtain a solution.
- DKT precipitates at slower cooling rate as Form A and at faster cooling rate as Form B.
- Form A is the thermodynamically stable form.
- This procedure is not easier than the method of EP668851 patent since this method uses solvent mixtures as well and Xylene is not a prefered solvent of choice by crystallization due to its high boiling point.
- This list can be expanded with other suitable solvents by holding on the spirit of the invention .
- the scope of the invention should not be limited to these solvents.
- Other suitable solvents especially from class of esters, ethers, ketone , halogenated organic solvents, aryl, alkyl hydrocarbons among others. Suitable solvent mixtures which do not dissolve DKT and less dissolve Dexketoprofen and Trometamol and lead to the desired polymorph may also be applied. But single solvents are more preferable.
- Reaction temperatures from 0 0 C to reflux may be applied . Applying heat may diminish reaction times. But this is not preferred since this may lead to degradation and polymorphic changes.
- Applied solvent amounts are typically around 10 times of reagent amounts. Less solvent may lead to increased reaction times .More solvent applied may lead to yield loss and expenditure.
- Solvents that lead to form A by applying this method are: Methylisobutyl keton,
- Solvents that lead to form B by applying this method are : n-Butyl acetate, Iso- propanol, n-propanol
- Example 1 In a 250 ml three necked round bottomed glass flask equipped with glass rod and teflon paddle 1O g Dexketoprofen is weighed and dissolved in 30 ml Ethanol. 4.8 g Trometamol is dissolved in 16 ml water and added to Dexketoprofen solution. Resulting solution is evaporated to dryness . 20 ml of Ethanol is added to the residue to dissolve and again evaporated to dryness. The solid residue is dissolved in 16 ml Ethanol at 55 0 C . 40 ml Ethylacetate is added . The obtained solution is cooled. Around 25°C precipitation occured.
- Polymorphic form is determined with PXRD ( See XRD Figure 3) ; 2 Theta : 4.66, 9.00, 12.54, 14.82, 17.12, 18.00, 20.30, 22.64, 27.30 and FT IR (See IR Figure 4) wavenumber (cm- 1) : 1630, 1554, 1426, 1354, 1083, 1043, 833
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des procédés simples, économiques et fiables pour préparer des polymorphes de dexkétoprofène trométamol de forme A et forme B.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2009/052821 WO2011001213A1 (fr) | 2009-06-30 | 2009-06-30 | Procédé pour préparer des cristaux de forme a et forme b de dexkétoprofène trométamol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2475636A1 true EP2475636A1 (fr) | 2012-07-18 |
Family
ID=41728307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP09786483A Withdrawn EP2475636A1 (fr) | 2009-06-30 | 2009-06-30 | Procédé pour préparer des cristaux de forme a et forme b de dexkétoprofène trométamol |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP2475636A1 (fr) |
| WO (1) | WO2011001213A1 (fr) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2058024B1 (es) * | 1992-11-10 | 1995-05-01 | Menarini Lab | Nuevo derivado arilpropionico, procedimiento de fabricacion del mismo y su utilizacion como analgesico. |
| EP1739072A1 (fr) * | 2005-06-15 | 2007-01-03 | Laboratorios Menarini S.A. | Formes polymorphiques du dexketoprofene trometamol, ainsi que leurs préparations et compositions pharmaceutiques les comprenant |
-
2009
- 2009-06-30 WO PCT/IB2009/052821 patent/WO2011001213A1/fr not_active Ceased
- 2009-06-30 EP EP09786483A patent/EP2475636A1/fr not_active Withdrawn
Non-Patent Citations (2)
| Title |
|---|
| None * |
| See also references of WO2011001213A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011001213A1 (fr) | 2011-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002366383B2 (en) | Polymorphs of clopidogrel hydrogensulfate | |
| US20100286417A1 (en) | Crystalline Minocycline Base and Processes for its Preparation | |
| US6767913B2 (en) | Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms | |
| KR101604501B1 (ko) | N-[2-(다이에틸아미노)에틸]-5-[(5-플루오로-1,2-다이하이드로-2-옥소-3h-인돌-3-일리덴)메틸]-2,4-다이메틸-1h-피롤-3-카복스아미드의 결정 형태 및 이의 제조 방법 | |
| ES2575000T3 (es) | Proceso mejorado para la preparación de ambrisentano | |
| CN102985416A (zh) | 制备凝血酶特异性抑制剂的方法 | |
| US20090099363A1 (en) | Process for the preparation of polymorphic forms of clopidogrel hydrogen sulfate | |
| CN106256824B (zh) | 一种高纯度德拉沙星葡甲胺盐的制备方法 | |
| WO2007109799A2 (fr) | Polymorphes de malate d'eszopiclone | |
| CZ20022000A3 (cs) | Způsoby přípravy a nová krystalická forma leflunomidu | |
| WO2012022240A1 (fr) | Nouveau cristal d'erlotinib sous forme de base et son procédé de préparation | |
| US20030225129A1 (en) | Polymorphs of clopidogrel hydrogensulfate | |
| US11325922B2 (en) | Process for the preparation of Crisaborole in a stable crystal form | |
| CA2493370C (fr) | Formes cristallines de l'olanzapine et procedes de preparation desdites formes | |
| WO2011001213A1 (fr) | Procédé pour préparer des cristaux de forme a et forme b de dexkétoprofène trométamol | |
| WO2011125069A1 (fr) | Procédé de préparation de la forme cristalline i du bisulfate de clopidogrel | |
| JP2025537211A (ja) | ジアステレオマー酒石酸エステルによりラセミ体を分割することによりフィネレノンを調製する方法 | |
| JP2025518760A (ja) | ピコリンアミド殺真菌剤化合物の結晶形態 | |
| KR101001646B1 (ko) | (r)-(+)-란소프라졸의 제조방법 및 이에 사용되는 중간체 | |
| EP2197273A1 (fr) | Procédé de préparation de r-gossypol l-phénylalaninol diénamine | |
| JP3644998B2 (ja) | ベンジリデン誘導体の結晶の選択的取得方法 | |
| US8546574B2 (en) | Conglomerates of tenatoprazole potassium salts | |
| WO2004007496A1 (fr) | Procede de preparation d'imidazo(1,2-a)pyridine-3-acetamides | |
| WO2013075732A1 (fr) | Procédé de préparation d'une forme cristalline i de l'étoricoxib | |
| ITMI20081732A1 (it) | Procedimento per la preparazione di azelnidipina cristallina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20120522 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20170403 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20170815 |